Picture of Epigenomics AG logo

ECX Epigenomics AG Share Price

0.000.00%
de flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m-3.69%
3m-15.68%
6m+128.84%
1yr+118.65%
Volume Change (%)
10d/3m-26.36%
Price vs... (%)
52w High-29.41%
50d MA-0.72%
200d MA+63.23%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-534.16%
Return on Equity-175.4%
Operating Margin-2464.51%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Epigenomics AG EPS forecast chart

Profile Summary

Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
June 29th, 2000
Public Since
July 19th, 2004
No. of Employees
18
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
de flag iconXETRA
Shares in Issue
866,351
Blurred out image of a map
Address
Geneststrasse 5, BERLIN, 10829
Web
https://www.epigenomics.com/
Phone
+49 30243450
Contact
Frederic Hilke
Auditors
Baker Tilly Roelfs AG Wirtschaftsprufungsgesellschaft

ECX Share Price Performance

Upcoming Events for ECX

Epigenomics AG Annual Shareholders Meeting

Q1 2024 Epigenomics AG Earnings Release

Similar to ECX

FAQ